Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04736966 · ClinicalTrials.gov registry record · Phase 1
Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT04736966 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 13 participants.
The verdict
NCT04736966, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
A Phase I clinical trial to determine the safety and tolerability of an anti-IL23 antibody for the treatment of patients with alcoholic liver disease
Interventions
- DRUG Guselkumab 30mg
- DRUG Guselkumab 70mg
- DRUG Guselkumab 100mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04736966
The ClinicalTrials.gov registry entry for NCT04736966 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Guselkumab 30mg is the first listed.
NCT04736966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04736966 about?
NCT04736966 is a clinical study titled "Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease". A Phase I clinical trial to determine the safety and tolerability of an anti-IL23 antibody for the treatment of patients with alcoholic liver disease
What is the current status of trial NCT04736966?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-03-03. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT04736966?
The interventions under investigation include: Guselkumab 30mg (DRUG), Guselkumab 70mg (DRUG), Guselkumab 100mg (DRUG).
Who is sponsoring clinical trial NCT04736966?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.